2 years ago
Overview of Ciltacabtagene Autoleucel Approval Ciltacabtagene Autoleucel: An Overview of Its Approval Journey From 2014 to 2022, it took Ciltacabtagene Autoleucel eight years to complete the journe...
2 years ago
March 1, 2022 FDA Approval Carvykti for the treatment of relapsed/refractory multiple myeloma FDA Approves Carvykti for Marketing On March 1, 2022, Genscript Biotech officially announced that its s...
2 years ago
🌈 มุมมองของผู้เชี่ยวชาญ: ตัวเลือกการรักษาด้วย CAR-T ในผู้ป่วยไทย🌈 https://www.medtourcn.com/wp-content/uploads/2024/03/480P泰英字-上海同济泰国患者医生吹一波CAR-T优势2.mp4 🌸 ในแผนกโรคเลือดข...
2 years ago
🌈Expert Perspective: Options for CAR-T Therapy in Thai Patients🌈 https://www.medtourcn.com/wp-content/uploads/2024/03/480P-上海同济泰国患者医生吹一波CAR-T优势2.mp4 🌺In the Hematology Dep...
2 years ago
🎉 #PNAS Breaking News: Revolutionary CAR-T Cell Therapy Successfully Treats Autoimmune Disease in China! 🎉 PNAS In a groundbreaking development, Chinese medical experts have achieved a milestone in...
2 years ago
Can CAR-T MM(multiple myeloma) be cured CAR-T therapy targeting antigens related to multiple myeloma has brought new hope for curing this disease in clinical medicine. Recent research findings have...
2 years ago
What are the products of CAR-T approved for multiple myeloma William Casler, a patient from France, was diagnosed with multiple myeloma in 2009, and his journey of fighting cancer has been long and...
2 years ago
Exploring the Frontier:CAR-T Trials for Multiple Myeloma and Their Transformative Impact Multiple myeloma (MM) treatment has made remarkable progress over the past two decades, significantly improv...
2 years ago
CAR-T in Multiple Mmyeloma,What are the CAR-T therapies approved by FDA and pending approval in 2024 Currently, the FDA has approved six CAR-T cell therapies Tisagenlecleucel (Kymriah) – Ind...
2 years ago
Abecma and Carvykti BCMA CAR-T Therapies Poised for Frontline Use, Market Size Expected to Expand Six-fold March 15,2024,the FDA Oncologic Drugs Advisory Committee (ODAC) held a full-day meeting to...
2 years ago
🩸 Breakthrough in Multiple Myeloma Treatment! 🩺 LANCET 🔬Targeting GPRC5D with CAR-T Cells shows immense potential in treating relapsed or refractory multiple myeloma patients. Multiple myeloma, a ...
2 years ago
T cell myeloma,The Lancet Haematology:GPRC5D-Targeted CAR-T Cell Therapy Shows Promising Potential for Relapsed or Refractory Multiple Myeloma OriCAR-017:a first-in-human, single-centre, single-arm...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
